PXMTF (PHAXIAM Therapeutics) Other Operating Expense: $-4.33 Mil (TTM As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics Other Operating Expense?

PHAXIAM Therapeutics PXMTF 38 Other Operating Expense is $-4.33 Mil as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

PHAXIAM Therapeutics's Other Operating Expense for the three months ended in Sep. 2023 was $-0.57 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.33 Mil.

PHAXIAM Therapeutics's quarterly Other Operating Expense increased from Dec. 2022 ($-3.76 Mil) to Jun. 2023 ($0.00 Mil) but then declined from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($-0.57 Mil).

PHAXIAM Therapeutics's annual Other Operating Expense declined from Dec. 2020 ($-2.39 Mil) to Dec. 2021 ($-2.89 Mil) and declined from Dec. 2021 ($-2.89 Mil) to Dec. 2022 ($-5.27 Mil).

PHAXIAM Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Other Operating Expense Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.46 -5.04 -2.39 -2.89 -5.27

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 -1.30 -3.76 0.00 -0.57
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-4.33 Mil mean?
PHAXIAM Therapeutics (PXMTF) has a Other Operating Expense of $-4.33 Mil as of Sep. 2023. Other operating expenses that a company records on its income statement. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Other Operating Expense too high?
PHAXIAM Therapeutics' current Other Operating Expense is $-4.33 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Other Operating Expense compare to VRTX and REGN?
PHAXIAM Therapeutics' Other Operating Expense of $-4.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Other Operating Expense is $-4.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current Other Operating Expense of $-4.33 Mil. The current Other Operating Expense is $-4.33 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current Other Operating Expense is $-4.33 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price